Podoplanin-CLEC2活化血小板与肿瘤相关性的研究进展

doi:10.11904/j.issn.1002-3070.2021.02.014

Abstract

Abstract: Podoplanin is a transmembrane sialate-like glycoprotein expressed on the surface of a variety of tumor cells.It is the endogenous ligand of platelet C-type lectin-like receptor(CLEC2).Podoplanin can induce powerful platelet aggregation through CLEC2,and participate in cancer-related thrombosis.Based on these findings,anti-podoplanin and anti-CLEC2 targeted drugs are expected to become new therapies for the treatment of tumors.This review will discuss deeply the role of podoplanin-CLEC2 activated platelets in tumorigenesis and development,and discuss how to develop podoplanin-CLEC2 as a therapeutic target.

Key words: Platelet;C-type lectin-like receptor 2;Podoplanin;Tumor;Thrombosis

CLC Number:

LI Mingming, YUE Chenxi, ZHANG Menglin, HUANG Wenjuan, WANG Ruitao. Research progress on the relationship between Podoplanin-CLEC2 activation of platelets and tumors[J]. Journal of Practical Oncology, 2021, 35(2): 174-178.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2021.02.014

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2021/V35/I2/174

References

1 Hisada Y,Mackman N.Cancer-associated pathways and biomarkers of venous thrombosis[J].Blood,2017,130(13):1499-1506.
2 Mukai M,Oka T.Mechanism and management of cancer-associated thrombosis[J].J Cardiol,2018,72(2):89-93.
3 Ünlü B,Versteeg HH.Cancer-associated thrombosis:the search for the holy grail continues[J].Res Pract Thromb Haemost,2018,2(4):622-629.
4 Li N,Yu Z,Zhang X,et al.Elevated mean platelet volume predicts poor prognosis in colorectal cancer[J].Sci Rep,2017,7(1):10261.
5 Yun ZY,Zhang X,Liu YS,et al.Lower mean platelet volume predicts poor prognosis in renal cell carcinoma[J].Sci Rep,2017,7(1):6700.
6 Takemoto A,Miyata K,Fujita N.Platelet-activating factor podoplanin:from discovery to drug development[J].Cancer Metastasis Rev,2017,36(2):225-234.
7 Miyata K,Takemoto A,Okumura S,et al.Podoplanin enhances lung cancer cell growth in vivo by inducing platelet aggregation[J].Sci Rep,2017,7(1):4059.
8 Nagae M,Morita-Matsumoto K,Kato M,et al.A platform of C-type lectin-like receptor CLEC-2 for binding O-glycosylated podoplanin and nonglycosylated rhodocytin[J].Structure,2014,22(12):1711-1721.
9 Tone K,Stappers MHT,Willment JA,et al.C-type lectin receptors of the Dectin-1 cluster:Physiological roles and involvement in disease[J].Eur J Immunol,2019,49(12):2127-2133.
10 Bieniasz-Krzywiec P,Martín-Pérez R,Ehling M,et al.Podoplanin-expressing macrophages promote lymphangiogenesis and lymphoinvasion in breast cancer[J].Cell Metab,2019,30(5):917-936.
11 Hu G,Zhong K,Chen W,et al.Podoplanin-positive cancer-associated fibroblasts predict poor prognosis in lung cancer patients[J].Onco Targets Ther,2018,11:5607-5619.
12 Qiao X,Sun Y,Zou Y,et al.Immunohistochemical staining of podoplanin is helpful in determining the microinvasion of cervical squamous cell carcinoma published online ahead of print[J].Ann Diagn Pathol,2020,46:151493.
13 Hsu YB,Huang CF,Lin KT,et al.Podoplanin,a potential therapeutic target for nasopharyngeal carcinoma[J].Biomed Res Int,2019,2019:7457013.
14 Eisemann T,Costa B,Harter PN,et al.Podoplanin expression is a prognostic biomarker but may be dispensable for the malignancy of glioblastoma[J].Neuro Oncol,2019,21(3):326-336.
15 Wolber P,Schwarz D,Niemczyk M,et al.Expression of podoplanin correlates with prognosis in nasopharyngeal carcinoma[J].Eur Arch Otorhinolaryngol,2020,277(4):1185-1190.
16 Kato Y,Kaneko MK,Kunita A,et al.Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC2[J].Cancer Sci,2008,99(1):54-61.
17 Riedl J,Preusser M,Nazari PM,et al.Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism[J].Blood,2017,129(13):1831-1839.
18 Cioca A,Cimpean AM,Ceausu RA,et al.Evaluation of podoplanin expression in hepatocellular carcinoma using RNAscope and immunohistochemistry-a preliminary report[J].Cancer Genomics Proteomics,2017,14(5):383-387.
19 Krishnan H,Rayes J,Miyashita T,et al.Podoplanin:an emerging cancer biomarker and therapeutic target[J].Cancer Sci,2018,109(5):1292-1299.
20 Astarita JL,Acton SE,Turley SJ.Podoplanin:emerging functions in development,the immune system,and cancer[J].Front Immunol,2012,3:283.
21 Martín-Villar E,Borda-d'Agua B,Carrasco-Ramirez P,et al.Podoplanin mediates ECM degradation by squamous carcinoma cells through control of invadopodia stability[J].Oncogene,2015,34(34):4531-4544.
22 Verma V,Chandrashekar C.Evaluation of SOX2 and podoplanin expression in oral epithelial dysplasia and its correlation with malignant transformation[J].J Investig Clin Dent,2019,10(4):e12450.
23 Shirai T,Inoue O,Tamura S,et al.C-type lectin-like receptor 2 promotes hematogenous tumor metastasis and prothrombotic state in tumor-bearing mice[J].J Thromb Haemost,2017,15(3):513-525.
24 Xu M,Wang X,Pan Y,et al.Blocking podoplanin suppresses growth and pulmonary metastasis of human malignant melanoma[J].BMC Cancer,2019,19(1):599.
25 Bieniasz-Krzywiec P,Martín-Pérez R,Ehling M,et al.Podoplanin-expressing macrophages promote lymphangiogenesis and lymphoinvasion in breast cancer[J].Cell Metab,2019,30(5):917-936.
26 Neinaa YME,El-Ashmawy AA,Alshenawy HA,et al.The prognostic value of podoplanin expression in nonmelanoma skin cancers:correlation with lymphatic vessel density[J].Am J Dermatopathol,2020,42(6):432-438.
27 Xie L,Lin C,Zhang Q,et al.Elevated expression of podoplanin and its clinicopathological,prognostic,and therapeutic values in squamous non-small cell lung cancer[J].Cancer Manag Res,2018,10:1329-1340.
28 Königsbrügge O,Pabinger I,Ay C.Risk factors for venous thromboembolism in cancer: novel findings from the Vienna Cancer and Thrombosis Study(CATS)[J].Thromb Res,2014,133(2):39-43.
29 Quintanilla M,Montero-Montero L,Renart J,et al.Podoplanin in inflammation and cancer[J].Int J Mol Sci,2019,20(3):707.
30 Payne H,Ponomaryov T,Watson SP,et al.Mice with a deficiency in CLEC2 are protected against deep vein thrombosis[J].Blood,2017,129(14):2013-2020.
31 Kunita A,Kashima TG,Morishita Y,et al.The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis[J].Am J Pathol,2007,170(4):1337-1347.
32 Lyman GH,Bohlke K,Khorana AA,et al.Venous thromboembolism prophylaxis and treatment in patients with cancer:american society of clinical oncology clinical practice guideline update 2014[J].J Clin Oncol,2015,33(6):654-656.
33 García Rodríguez LA,Martín-Pérez M,Hennekens CH,et al.Bleeding risk with long-term low-dose aspirin:a systematic review of observational studies[J].PLoS One,2016,11(8):e0160046.
34 Sekiguchi T,Takemoto A,Takagi S,et al.Targeting a novel domain in Podoplanin for inhibiting platelet-mediated tumor metastasis[J].Oncotarget,2016,7(4):3934-3946.
35 Kato Y,Kaneko MK,Kuno A,et al.Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain[J].Biochem Biophys Res Commun,2006,349(4):1301-1307.
36 Sekiguchi T,Takemoto A,Takagi S,et al.Targeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasis[J].Oncotarget,2016,7(4):3934-3946.
37 Abe S,Kaneko MK,Tsuchihashi Y,et al.Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model[J].Cancer Sci,2016,107(9):1198-1205.
38 Nishinaga Y,Sato K,Yasui H,et al.Targeted phototherapy for malignant pleural mesothelioma:near-Infrared photoimmunotherapy targeting podoplanin[J].Cells,2020,9(4):1019.
39 Sudo H,Tsuji AB,Sugyo A,et al.Therapeutic efficacy evaluation of radioimmunotherapy with 90 Y-labeled anti-podoplanin antibody NZ-12 for mesothelioma[J].Cancer Sci,2019,110(5):1653-1664.
40 Kato Y,Kaneko MK.A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin[J].Sci Rep,2014,4:5924.
41 Bender M,May F,Lorenz V,et al.Combined in vivo depletion of glycoprotein VI and C-type lectin-like receptor 2 severely compromises hemostasis and abrogates arterial thrombosis in mice[J].Arterioscler Thromb Vasc Biol,2013,33(5):926-934.
42 Hughes CE,Navarro-Núñez L,Finney BA,et al.CLEC2 is not required for platelet aggregation at arteriolar shear[J].J Thromb Haemost,2010,8(10):2328-2332.
43 Tsukiji N,Osada M,Sasaki T,et al.Cobalt hematoporphyrin inhibits CLEC2-podoplanin interaction,tumor metastasis,and arterial/venous thrombosis in mice[J].Blood Adv,2018,2(17):2214-2225.
44 Sasaki T,Shirai T,Tsukiji N,et al.Functional characterization of recombinant snake venom rhodocytin:rhodocytin mutant blocks CLEC-2/podoplanin-dependent platelet aggregation and lung metastasis[J].J Thromb Haemost,2018,16(5):960-972.

[1]	LI Ji, CHEN Yang, ZHANG Maorong, YANG Zhao, TANG Xian, WEN Hongmei. Analysis of proportion and trend prediction of disability-adjusted life years attributed to aging population in common digestive system malignant tumors in China [J]. Journal of Practical Oncology, 2025, 39(5): 372-380.
[2]	ZHOU Suxia, XU Zhihua, GUO Shuling, FAN Ning, XU Lili. Analysis for the prevalence trend of malignant tumor incidence and mortality in cancer registration areas in Qinghai Province from 2014 to 2021 [J]. Journal of Practical Oncology, 2025, 39(5): 381-387.
[3]	REN Fanghan, ZHU Tiancen, LI Yanxia, CHEN Lili, NA Jun, TIAN Yuanmeng, MU Huijuan. Analysis of the incidence and mortality of lymphoma in cancer registration areas of Liaoning Province from 2016 to 2020 and their changing trends [J]. Journal of Practical Oncology, 2025, 39(5): 388-392.
[4]	LIU Lu, ZHU Jiahe, WANG Jia, ZHANG Bolun, XING Dehao, DING Gaoheng, WEI Xingmin, LIU Yuqin. Prediction analysis of incidence trend and age-period-cohort model of esophageal cancer in cancer registration areas of Gansu Province from 2010 to 2021 [J]. Journal of Practical Oncology, 2025, 39(5): 393-399.
[5]	LIU Yang, WANG Ying, MA Xiang, SONG JiaBao, LIU DaMin, CHEN Lili. Analysis of incidence and mortality of malignant tumors among urban residents in Yingkou City,Liaoning Province in 2021 [J]. Journal of Practical Oncology, 2025, 39(5): 400-404.
[6]	LI Yun, SHI Pinghui. Analysis of gastroscopic screening and follow-up results among high-risk populations for gastric cancer in Gejiu City,Yunnan Province [J]. Journal of Practical Oncology, 2025, 39(5): 405-411.
[7]	LI Yifan, QIN Chuanyu, ZENG Xi, LU Yajiao, LIAO Guangdong, KANG Leni, YANG Ying, ZHOU Min, XI Mingrong, YANG Chunxia, LI Jing. Analysis of the acceptance and influencing factors of self-collection urine HPV testing in cervical cancer screening [J]. Journal of Practical Oncology, 2025, 39(5): 412-417.
[8]	LI Xudong, LIU Tong. The single cell transcriptome sequencing reveals the role and prognostic value of PCLAF and ERO1A in the progression of breast cancer [J]. Journal of Practical Oncology, 2025, 39(5): 418-427.
[9]	ZHANG Xuan, LI Juan, FANG Chuanfeng, TIAN Hong, LIU Jiaren. Research progress of phytochemicals in tumor immunotherapy [J]. Journal of Practical Oncology, 2025, 39(5): 428-432.
[10]	XIN Xin, XIONG Wenjing, ZHANG Chunnuan, LI Xiaojing, GAO Xue, ZHANG Yue. Lactylation modification:an emerging target in cancer therapy [J]. Journal of Practical Oncology, 2025, 39(5): 433-436.
[11]	ZHOU Qing, WANG Yamei. Research progress on epigenetic regulation mechanism of oral adenoid cystic carcinoma [J]. Journal of Practical Oncology, 2025, 39(5): 437-444.
[12]	LUO Qiyuan, SHAO Hongchao, ZHOU Shaohua, YE Mushi. The current research status and prospect of the pathogenesis,influencing factors and surgical prevention and treatment strategies of inguinal hernia after prostate cancer surgery [J]. Journal of Practical Oncology, 2025, 39(5): 445-449.
[13]	LYU Rui, ZHEN Linlin. Research progress on bone microenvironment-mediated drug resistance in breast cancer bone metastasis [J]. Journal of Practical Oncology, 2025, 39(5): 450-456.
[14]	LI Ji, ZHANG Maorong, YANG Zhao, WEN Hongmei, WU Fuxian, LI Yuntao. Analyses for the incidence and mortality characteristics of malignant tumors in the cancer registration areas of Kunming City,Yunnan Province in 2020 and their trend from 2016 to 2020 [J]. Journal of Practical Oncology, 2025, 39(3): 169-176.
[15]	ZHAO Entong, GUAN Xin, LI Hongyan, QIU Yunting, ZHANG Bingqiang, CHEN Mengmeng, ZOU Wei, QU Chao. SNG162 activates the estrogen signaling pathway at the membrane initiation of glioblastoma by upregulating ER-α36 expression [J]. Journal of Practical Oncology, 2025, 39(3): 177-183.

Research progress on the relationship between Podoplanin-CLEC2 activation of platelets and tumors

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments